Phase 2
N=17
Effects of Octanoic Acid for Treatment of Essential Voice Tremor
Essential Voice Tremor · Vocal Tremor · Voice Tremor · Essential Tremor of Voice
Bottom Line
View on ClinicalTrials.gov: NCT01864525 ↗Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Aug 2018
Primary outcome: Primary: Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor — 12.91; 13.49; 12.43; 9.35 percentage of voice signal with tremor — p=0.0216
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Octanoic acid (Drug); Inactive capsule (Drug)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- Syracuse University
- Primary completion
- Dec 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor |
12.91; 13.49; 12.43; 9.35; 5.57; 5.19 | 0.0216 sig |
| SECONDARY Auditory-perceptual Tremor Severity Ratings |
1.25; 1.53; 1.63; 1.19 | 0.7172 |
Summary
Essential voice tremor is a neurological condition that produces a regular, shaking quality in the voice. One form of drug treatment that produces some improvement in tremor of the hands is octanoic acid, which is a food additive that is similar to alcohol. Research suggests that octanoic acid may reduce tremor in the hands/arms with few side effects and no intoxication effects. This study will determine whether octanoic acid may be useful for reducing tremor when it affects the voice. Researchers are hypothesizing that octanoic acid will reduce the effects of tremor on the voice.
Eligibility Criteria
Inclusion Criteria
- Participants have a diagnosis of essential voice tremor and show signs of tremor during the endoscopy examination (when pictures of the voice box are obtained)during screening appointment
- Participants show measurable voice tremor from recordings of the voice during screening appointment
Exclusion Criteria
- Participants have a diagnosis or show signs of Parkinson's Disease or another non-essential tremor movement disorder
- Participants have a diagnosis or show signs of spasmodic dysphonia (a different neurological voice disorder)
- Participants have a diagnosis of a severe, non-stable medical condition, such as kidney or liver failure, severe heart disease, severe lung disease, severe metabolic disease, uncontrolled hyperthyroidism, or other life-threatening disease such as active cancer
- Participants have a diagnosis of diabetes mellitus
- Participants are unable to suspend/stop a medication that they are currently taking for tremor or voice disorder for 12 weeks to complete this study
- Participants have a dependence on alcohol or allergy to alcohol
- Participants are pregnant or lactating
- Participants have an allergy to soy
- Participants have Irritable Bowel Syndrome
Data sourced from ClinicalTrials.gov (NCT01864525). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.